Wall Street analysts predict that Adamas Pharmaceuticals Inc (NASDAQ:ADMS) will announce earnings per share of ($1.32) for the current quarter, Zacks reports. Two analysts have provided estimates for Adamas Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($1.05) and the lowest estimate coming in at ($1.50). Adamas Pharmaceuticals posted earnings of ($0.72) per share during the same quarter last year, which would indicate a negative year over year growth rate of 83.3%. The company is expected to announce its next earnings results on Tuesday, May 8th.
On average, analysts expect that Adamas Pharmaceuticals will report full year earnings of ($5.53) per share for the current fiscal year, with EPS estimates ranging from ($6.56) to ($3.66). For the next financial year, analysts forecast that the firm will report earnings of ($2.98) per share, with EPS estimates ranging from ($4.30) to ($0.68). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Adamas Pharmaceuticals.
Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.18) by ($0.09). The business had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.84 million. The business’s quarterly revenue was up 1435.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.68) EPS.
Shares of Adamas Pharmaceuticals (NASDAQ ADMS) traded down $1.12 during trading hours on Wednesday, reaching $25.45. The company’s stock had a trading volume of 501,093 shares, compared to its average volume of 1,096,404. The company has a market capitalization of $770.17, a price-to-earnings ratio of -6.43 and a beta of 1.59. The company has a current ratio of 10.79, a quick ratio of 10.69 and a debt-to-equity ratio of 1.55. Adamas Pharmaceuticals has a 1-year low of $13.50 and a 1-year high of $44.00.
Several hedge funds have recently bought and sold shares of ADMS. JPMorgan Chase & Co. increased its position in shares of Adamas Pharmaceuticals by 13,028.4% during the third quarter. JPMorgan Chase & Co. now owns 136,273 shares of the specialty pharmaceutical company’s stock valued at $2,839,000 after acquiring an additional 135,235 shares during the last quarter. American Century Companies Inc. purchased a new stake in shares of Adamas Pharmaceuticals during the fourth quarter valued at approximately $2,110,000. Hikari Power Ltd purchased a new stake in shares of Adamas Pharmaceuticals during the third quarter valued at approximately $635,000. Prosight Management LP purchased a new stake in shares of Adamas Pharmaceuticals during the fourth quarter valued at approximately $407,000. Finally, EAM Investors LLC purchased a new stake in shares of Adamas Pharmaceuticals during the third quarter valued at approximately $1,795,000. Institutional investors own 77.25% of the company’s stock.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.